Filing Flows › AstraZeneca (AZN) › Q3 2026 › vs Q3 2025
AstraZeneca (AZN) Q3 2026 vs Q3 2025 (year over year)
AstraZeneca's revenue rose $1.0B (+7%) from $15.2B in Q3 2025 to $16.2B in Q3 2026. Gross margin 81.8% against 81.6% (+0.3 pts).
AstraZeneca, Q3 2026: revenue $16.2B (+7% year over year), operating margin 27.1%, net earnings $3.1B, operating cash flow $5.8B. The chart draws each line against Q3 2025, the increases inside each band.
Margins
| Q3 2026 | Q3 2025 | Change | |
|---|---|---|---|
| Gross margin | 81.8% | 81.6% | +0.3 pts |
| Operating margin | 27.1% | 23.6% | +3.5 pts |
| Net margin | 19.2% | 16.7% | +2.5 pts |
Every line
| Line | Q3 2026 | Q3 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $16.2B | $15.2B | $1.0B | +7% |
| Gross profit | $13.3B | $12.4B | $873M | +7% |
| Cost of revenue | $2.9B | $2.8B | $145M | +5% |
| Operating profit | $4.4B | $3.6B | $804M | +22% |
| Operating expenses | $8.9B | $8.8B | $69.0M | +0.8% |
| Pre-tax earnings | $4.0B | $3.2B | $714M | +22% |
| Other expense, net | $429M | $339M | $90.0M | +27% |
| Net earnings | $3.1B | $2.5B | $581M | +23% |
| Income tax | $842M | $709M | $133M | +19% |
Questions
How much did AstraZeneca's revenue grow year over year in Q3 2026?
AstraZeneca's revenue rose $1.0B (+7%) from $15.2B in Q3 2025 to $16.2B in Q3 2026. Gross margin 81.8% against 81.6% (+0.3 pts).